Johnson & Johnson (JNJ) Dividend Coverage Ratio (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Dividend Coverage Ratio came in at 1.71 in Q2 2026, down 3.09% year-over-year from 1.77 in Q2 2025, and up 2.57% quarter-over-quarter from 1.67 in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Dividend Coverage Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Dividend Coverage Ratio across 18 years of filings, most recently posting 1.71 for Q2 2026.
- In Q2 2026, Dividend Coverage Ratio fell 3.09% year-over-year to 1.71; the TTM figure through Jun 2026 stood at 1.67 (down 11.09% YoY), while the FY2025 annual figure was 2.16, up 81.97% from the prior year.
- Dividend Coverage Ratio came in at 1.71 for Q2 2026 at Johnson & Johnson, up from 1.67 in the prior quarter.
- In the past five years, Dividend Coverage Ratio ranged from a high of 9.07 in Q4 2023 to a low of 0.02 in Q2 2023.
- Average Dividend Coverage Ratio over 5 years is 1.98, with a median of 1.64 recorded in 2025.
- Year-over-year, Dividend Coverage Ratio slumped 101.27% in 2023 and surged 5008.56% in 2024.
- Over 5 years, Dividend Coverage Ratio stood at 1.82 in 2022, then decreased by 22.28% to 1.41 in 2023, then decreased by 18.64% to 1.15 in 2024, then soared by 42.11% to 1.63 in 2025, then increased by 4.95% to 1.71 in 2026.
- Per Business Quant data, the three most recent Dividend Coverage Ratio figures were 1.71 in Q2 2026, 1.67 in Q1 2026, and 1.63 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.93 Bn | 626.17 Bn | 17.26 Bn | 1.71 |
| 2 | AbbVie | 442.15 Bn | 435.58 Bn | 12.70 Bn | 1.18 |
| 3 | Merck | 364.76 Bn | 357.62 Bn | 12.21 Bn | -0.62 |
| 4 | Novartis Ag | 267.96 Bn | 260.27 Bn | 11.24 Bn | 1.14 |
| 5 | Pfizer | 158.75 Bn | 147.05 Bn | 10.94 Bn | -0.10 |
| 6 | Sanofi | 52.55 Bn | 45.17 Bn | 10.79 Bn | 0.07 |
| 7 | Revolution Medicines | 44.13 Bn | 44.13 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.80 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.33 Bn | 18.67 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 1.71 |
| Mar 29, 2026 | 1.67 |
| Dec 28, 2025 | 1.63 |
| Sep 28, 2025 | 1.64 |
| Jun 29, 2025 | 1.77 |
| Mar 30, 2025 | 3.68 |
| Dec 29, 2024 | 1.15 |
| Sep 29, 2024 | 0.90 |
| Jun 30, 2024 | 1.57 |
| Mar 31, 2024 | 1.13 |
| Dec 31, 2023 | 1.41 |
| Oct 1, 2023 | 9.07 |
| Jul 2, 2023 | 1.66 |
| Apr 2, 2023 | -0.02 |
| Jan 1, 2023 | 0.85 |
| Apr 3, 2022 | 1.82 |
| Oct 3, 2021 | 1.31 |
| Jul 4, 2021 | 2.25 |
| Apr 4, 2021 | 2.33 |
| Jan 3, 2021 | 0.65 |